

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

PROPOSED TERMINATION OF EXISTING SHARE OPTION SCHEME AND ADOPTION OF SHARE OPTION SCHEME

The board of directors (the “**Board**”) of Sirnaomics Ltd. (the “**Company**”) is pleased to announce that, on April 22, 2026 (after trading hours), the Board has proposed the adoption of a share option scheme (the “**2026 Share Option Scheme**”) and the termination of the existing share option scheme of the Company adopted on June 28, 2022 (the “**Existing Share Option Scheme**”) for the approval by the shareholders of the Company (the “**Shareholders**”).

THE EXISTING SHARE OPTION SCHEME

The Existing Share Option Scheme was adopted by way of a shareholder’s resolution passed on June 28, 2022 and is valid and effective for a period of ten years from the date of adoption. According to the terms of the Existing Share Option Scheme, the Company may at any time resolve to terminate the Existing Share Option Scheme before the end of its life and in such event, no further options may be granted but the provision of the Existing Share Option Scheme shall remain in force and effect to the extent necessary to give effect to the exercise of any options granted prior to its termination or otherwise as may be required in accordance with the provisions of the Existing Share Option Scheme. Options granted under the Existing Share Option Scheme prior to such termination shall continue to be valid and exercisable in accordance with their terms of grant.

The Board has no intention of granting any further option under the Existing Share Option Scheme during the period from the date of this announcement and up to the date of the forthcoming general meeting of the Company.

PROPOSED ADOPTION OF THE 2026 SHARE OPTION SCHEME

The Company proposes to adopt the 2026 Share Option Scheme in accordance with the latest requirements of Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) published by The Stock Exchange of Hong Kong (the “**Stock Exchange**”) that came into effect on January 1, 2023. The purpose of the 2026 Share Option Scheme will provide the Company with a flexible means of retaining, incentivizing, rewarding, remunerating, compensating and/or providing benefits to eligible participants.

The adoption of the 2026 Share Option Scheme is conditional upon:

- (i) the passing of an ordinary resolution by the Shareholders at the general meeting of the Company to approve and adopt the 2026 Share Option Scheme and to authorize the Board to grant share options to subscribe for Shares thereunder and to allot, issue and deal with Shares pursuant to the exercise of any share options granted under the 2026 Share Option Scheme; and
- (ii) the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, any Shares to be issued pursuant to the exercise of share options granted under the 2026 Share Option Scheme.

An extraordinary general meeting (the “**EGM**”) will be convened for the Shareholders to consider and, if thought fit, pass the ordinary resolution to approve, inter alia, the adoption of the 2026 Share Option Scheme.

A circular containing, among others, (i) details of the adoption of the 2026 Share Option Scheme; (ii) the principal terms of the 2026 Share Option Scheme; and (iii) a notice of convening the extraordinary general meeting, is expected to be despatched to the Shareholders in accordance with the requirements of the Listing Rules in due course.

By order of the Board

Sirnaomics Ltd.

Dr. Poon Hung Fai

Chairman and Chief Executive Director

Hong Kong, April 22, 2026

As at the date of this announcement, the Board comprises Dr. Poon Hung Fai as executive Director, Mr. Ouyang Yunlong and Dr. Yin Huijun as non-executive Directors, and Mr. Wong Yu Shan Eugene, Dr. Zhang Peng and Ms. Lo Yee Hang as independent non-executive Directors.